Here are 1-3 brief analogies for Neogen:

• Labcorp for food safety diagnostics.
• IDEXX Laboratories for animal health, plus farm and vet supplies.

• Food & Feed Safety Diagnostic Test Kits: Kits designed to detect a wide range of dangerous or unintended substances in food and animal feed, including pathogens, allergens, and toxins.
• Rapid Sanitation Tests: Products like AccuPoint Advanced that quickly assess sanitation levels by detecting adenosine triphosphate (ATP).
• Veterinary Instruments: A variety of tools and equipment used in animal care and veterinary practices.
• Animal Pharmaceuticals & Vaccines: Medications and immunological agents for treating and preventing diseases in animals.
• Animal Hygiene & Pest Control Products: Products such as cleaners, disinfectants, insecticides, and rodenticides to maintain sanitary conditions and manage pests in animal environments.
• Animal Genomics Testing Services: Services providing genetic analysis for various animal safety and improvement applications.
• Drug Detection Test Kits: Immunoassay kits used to detect abused, therapeutic, or residual drugs in animals and for human forensic toxicology.

Based on the provided company description, Neogen Corporation primarily sells its products to other companies and organizations, rather than individuals. The background information describes various categories of business customers but does not list specific customer company names.

Neogen's major customer categories include:

• Food and Feed Processors: This broad category encompasses a wide range of businesses, including grain producers and processors, producers of various processed foods (such as cookies, crackers, candy, ice cream), meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies.
• Laboratories and Producers of Related Products: This includes laboratories in general, as well as producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products that utilize Neogen's diagnostic and sanitation testing products.
• Animal Safety Market Participants: This segment serves researchers, professionals in the veterinary field, and facilities involved with farm and racing animals, for products ranging from veterinary instruments and pharmaceuticals to genomics testing and drug detection kits.
• Distributors and Retail Chains: Neogen sells its products directly to these entities, which then distribute or resell the products to end-users.

Mike Nassif, Chief Executive Officer and President

Mike Nassif brings over two decades of global leadership experience across the healthcare, diagnostics, biopharma, and consumer goods sectors. Prior to joining Neogen, he served as Global President of Point of Care Diagnostics at Siemens Healthineers. He also held senior leadership roles at Baxter Healthcare, AB-InBev, and Johnson & Johnson, where he led business turnarounds, innovation strategies, digital transformations, and commercial operations on a global scale. Nassif was a Captain in the United States Army Corps of Engineers. He holds a Bachelor's in Civil Engineering from the United States Military Academy at West Point and an MBA in Finance from the Wharton School.

Bryan Riggsbee, Chief Financial Officer

Bryan Riggsbee has more than 25 years of financial leadership experience in the diagnostics and healthcare industries. He joined Neogen from bioMérieux, where he served as Chief Financial Officer of its North American business. Previously, he spent nearly a decade as CFO of Myriad Genetics, where he led finance, accounting, and investor relations, and helped expand the company's portfolio and international reach. His earlier career includes senior finance roles at LabCorp, GE, and KPMG. Riggsbee holds bachelor's degrees in political science from the University of North Carolina at Chapel Hill and in accounting from North Carolina State University, along with an MBA from Northwestern University's Kellogg School of Management. He is also a Certified Public Accountant (CPA).

Kevin Burke, Chief Human Resources Officer

Kevin Burke brings over two decades of global HR leadership experience across the manufacturing and life sciences sectors. Prior to Neogen, he held senior HR roles at Superior Industries, Valeo, Lear Corporation, and Dow Performance Silicones, where he led global talent management and organizational development initiatives. He holds a Bachelor of Arts in Organizational Communication, a Master's degree in Human Resources, and an MBA in General Management from Northwestern University's Kellogg School of Management.

Joe Freels, Senior Vice President and Chief Commercial Officer

Joe Freels has more than 20 years of leadership experience across diagnostics, life sciences, and global commercial operations. Before joining Neogen, he served as Senior Vice President of Global Commercial Operations at Cepheid, a Danaher Company, where he led worldwide commercial strategy and contributed to significant revenue and market share growth.

Dr. Tammi Ranalli, Senior Vice President and General Manager, Global Food Safety

Dr. Tammi Ranalli, who joined Neogen in January 2026, brings over 20 years of leadership experience across molecular and point-of-care diagnostics, product development, and global business operations. Most recently, she served as Senior Vice President of the Molecular Diagnostics and Point-of-Care Diagnostics Business Units at QuidelOrtho, managing a portfolio across infectious disease, cardiometabolic, and toxicology segments.

The key risks to Neogen Corporation (NEOG) primarily stem from its recent significant acquisition and the highly regulated and competitive nature of its operating sectors.

1. Acquisition Integration Risks: Neogen faces substantial challenges related to the integration of the former 3M Food Safety business. This integration has resulted in persistent production inefficiencies, increased distribution and integration costs, and elevated inventory write-offs. The company has also recorded massive non-cash goodwill impairment charges, signifying that the acquired assets were not worth the initial valuation. These operational and financial difficulties have contributed to a decreased sales outlook and significant net losses, impacting overall profitability and financial flexibility. Furthermore, the integration process has been a subject of class-action lawsuits alleging misleading statements regarding its progress and negative financial impact.
2. Intense Competition and Technological Obsolescence: Neogen operates in a dynamic and highly competitive market for both food and animal safety diagnostic solutions and genomics services. Competitors, including large multinational corporations and specialized firms, continually introduce technological advancements in rapid testing and leverage substantial research and development budgets. A failure to innovate, keep pace with emerging technologies, or effectively compete on pricing could erode Neogen's market share and profitability.
3. Regulatory Changes and Product Liability: The food and animal safety industries are subject to stringent regulations. Changes in food safety standards, animal health regulations, or approval processes could significantly impact the demand for Neogen's products or require costly adaptations. Additionally, given that Neogen's products are designed to detect dangerous substances and ensure safety, there is a inherent risk of product liability claims, recalls, or reputational damage if a product fails or is alleged to cause harm. Recent events, such as a voluntary recall of a veterinary product due to microbial contamination and lawsuits alleging failure to warn about potential harm from a veterinary ointment, highlight these risks.

Neogen Corporation (NEOG) operates in two main segments: Food Safety and Animal Safety. The company's management has provided estimates for its addressable markets within these segments.

Food Safety

Neogen estimates its addressable market for the food safety category to be approximately $5 billion globally. This segment includes products for detecting foodborne pathogens, spoilage organisms, natural toxins, food allergens, and general sanitation concerns. For broader context, the global food safety testing market was estimated at approximately USD 26.90 billion in 2025 and is projected to reach around USD 51.88 billion by 2034.

Animal Safety

For its Animal Safety segment, which encompasses veterinary instruments, pharmaceuticals, vaccines, diagnostic products, and genomics testing services, Neogen's management anticipates a Total Addressable Market (TAM) of around $6 billion globally. The global animal health market was estimated to be between USD 68.7 billion in 2025 and USD 73.10 billion in 2025, with projections to grow to approximately USD 156.0 billion by 2033 or USD 172.08 billion by 2035.

Overall Addressable Market

Combined, Neogen's management estimates its overall addressable market for food and animal safety solutions to be approximately $11 billion globally.

Share Repurchases

• Neogen reported net repurchases of common shares amounting to USD -451.0 thousand in fiscal year 2025.
• Management has indicated openness to using proceeds from divestments for future share repurchases, alongside debt reduction.

Share Issuance

• The merger with 3M's Food Safety business, completed in September 2022, resulted in 3M shareholders receiving approximately 50.1% of the combined company, representing a significant share issuance.
• As of November 30, 2024, the company had 216,944,017 shares of Common Stock outstanding.
• Share issuance in fiscal year 2025 included exercises of options, restricted stock units (RSUs), and shares under an employee stock purchase plan.

Outbound Investments

• Neogen completed a significant merger with 3M's Food Safety business in September 2022, involving a payment of approximately $1 billion to 3M. This acquisition expanded Neogen's capabilities in food safety testing and global reach.
• In July 2025, Neogen divested its global Cleaners & Disinfectants business for $130 million, with $100 million of the net proceeds designated for debt reduction.
• Neogen announced in March 2026 its plan to divest its global animal genomics business to Zoetis for $160 million, with the net proceeds primarily intended for debt reduction.

Capital Expenditures

• Capital expenditures for fiscal year 2025 were projected at approximately $105 million, largely driven by integration activities following the 3M Food Safety acquisition.
• Capital expenditures are expected to decrease significantly to around $50 million in fiscal year 2026.
• A key focus of recent capital expenditures includes investments in R&D, sales/marketing, and essential product lines such as Petrifilm, including the establishment of a new Petrifilm production facility in Lansing, Michigan, anticipated to be fully operational by November 2026.